Kura Oncology, Inc.
KURA · Nasdaq · United States
Share price · KURA
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when KURA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 4 Nov 2026-23.0%
- 28 Oct 2026+8.3%
Nothing announced by KURA that day or the session before.
- 25 Aug 2026+9.6%
Nothing announced by KURA that day or the session before.
- 18 Aug 2026+9.3%
Nothing announced by KURA that day or the session before.
- 14 Aug 2026+7.6%
Nothing announced by KURA that day or the session before.
- 28 Jul 2026-8.3%
- 7 Jul 2026+8.6%
Nothing announced by KURA that day or the session before.
- 1 Jun 2026-11.4%
Nothing announced by KURA that day or the session before.
- 26 May 2026-7.5%
Nothing announced by KURA that day or the session before.
- 21 May 2026+7.6%
Nothing announced by KURA that day or the session before.
Share of unusual movement by asset
For each asset, the share of KURA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | MeninSmall molecule | Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia Relapsed/Refractory Acute Myeloid Leukemia | |
| Phase 1 | FarnesyltransferaseSmall molecule | Non-Small Cell Lung CancerRenal Cell Carcinoma Clear Cell Renal Cell Carcinoma |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
March 2027 (1)
What to watch
2028 (1)
October 2028 (1)
What to watch
2031 (1)
November 2031 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (17)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $23M | $67M | $58M+ $434M short-term inv. | $70M-$54M operating cash flow | report ↗ |
View 16 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $21M | $62M | $70M+ $449M short-term inv. | $68M-$63M operating cash flow | report ↗ |
| 2026-Q1 | $18M | $65M | $39M+ $542M short-term inv. | $73M-$86M operating cash flow | report ↗ |
| 2025-Q4 | $17M | $64M | $667M | $81M | report ↗ |
| 2025-Q3 | $21M | $68M | $95M+ $454M short-term inv. | $74M-$81M operating cash flow | report ↗ |
| 2025-Q2 | $15M | $63M | $82M+ $549M short-term inv. | $66M-$29M operating cash flow | report ↗ |
| 2025-Q1 | $18M | $56M | $658M | $73M | report ↗ |
| 2024-Q3 | — | $42M | $49M+ $406M short-term inv. | $54M-$43M operating cash flow | report ↗ |
| 2024-Q2 | — | $40M | $45M+ $446M short-term inv. | $51M-$43M operating cash flow | report ↗ |
| 2024-Q1 | — | $36M | $42M+ $486M short-term inv. | $50M-$49M operating cash flow | report ↗ |
| 2023-Q3 | — | $29M | $29M+ $424M short-term inv. | $39M-$29M operating cash flow | report ↗ |
| 2023-Q2 | — | $28M | $49M+ $428M short-term inv. | $37M-$26M operating cash flow | report ↗ |
| 2023-Q1 | — | $25M | $27M+ $379M short-term inv. | $34M-$36M operating cash flow | report ↗ |
| 2022-Q3 | — | $25M | $91M+ $337M short-term inv. | $36M-$21M operating cash flow | report ↗ |
| 2022-Q2 | — | $24M | $39M+ $411M short-term inv. | $35M-$30M operating cash flow | report ↗ |
| 2022-Q1 | — | $21M | $34M+ $446M short-term inv. | $32M-$32M operating cash flow | report ↗ |
| 2021-Q3 | — | $22M | $39M+ $504M short-term inv. | $33M-$25M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $68M | $251M | $667M | $295M | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | — | $727M | — | report ↗ |
| 2023-FY | $0 | $115M | $37M+ $387M short-term inv. | $38M-$125M operating cash flow | report ↗ |
| 2022-FY | — | $93M | $52M+ $386M short-term inv. | $34M-$110M operating cash flow | report ↗ |
| 2021-FY | — | $85M | $91M+ $427M short-term inv. | $33M-$105M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 6 purchases ($5.4M), 44 sales ($4.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-19 | Powl Brian T. · Chief Commercial Officer | Open-market sale | 448 | $7.27 | $3K | Form 4 |
| 2026-11-17 | FORD KATHLEEN · Chief Operating Officer | Open-market sale | 3,668 | $7.46 | $27K | Form 4 |
| 2026-11-17 | Powl Brian T. · Chief Commercial Officer | Open-market sale | 15,254 | $7.45 | $114K | Form 4 |
| 2026-11-17 | Leoni Mollie · Chief Medical Officer | Open-market sale | 22,241 | $7.45 | $166K | Form 4 |
| 2026-11-16 | FORD KATHLEEN · Chief Operating Officer | Open-market sale | 7,042 | $7.44 | $52K | Form 4 |
| 2026-11-16 | Bair Teresa Brophy · Chief Legal Officer | Open-market sale | 8,601 | $7.44 | $64K | Form 4 |
| 2026-11-16 | Powl Brian T. · Chief Commercial Officer | Open-market sale | 9,196 | $7.44 | $68K | Form 4 |
| 2026-11-16 | Leoni Mollie · Chief Medical Officer | Open-market sale | 19,009 | $7.44 | $141K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 218 reporting institutions held 84.4M shares ($675.4M, 91.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 9,637,531 | $78.4M |
| 2 | SUVRETTA CAPITAL MANAGEMENT, LLC | 8,575,422 | $69.7M |
| 3 | BVF INC/IL | 8,445,769 | $68.7M |
| 4 | STATE STREET CORP | 4,511,891 | $36.7M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 3,785,685 | $30.8M |
| 6 | ARMISTICE CAPITAL, LLC | 3,736,000 | $30.4M |
| 7 | Prosight Management, LP | 3,356,700 | $27.3M |
| 8 | Deep Track Capital, LP | 2,643,542 | $21.5M |
| 9 | AQR CAPITAL MANAGEMENT LLC | 2,124,480 | $17.3M |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 2,034,276 | $16.5M |
| 11 | Qube Research & Technologies Ltd | 1,636,733 | $13.3M |
| 12 | RENAISSANCE TECHNOLOGIES LLC | 1,582,568 | $12.9M |
| 13 | MILLENNIUM MANAGEMENT LLC | 1,565,143 | $12.7M |
| 14 | ALETHEA CAPITAL MANAGEMENT, LLC | 1,529,369 | $12.4M |
| 15 | GOLDMAN SACHS GROUP INC | 1,433,471 | $11.7M |